Bloodworks Northwest Report issue

Foundation Phase 2

Organization Overview

First Clinical Trial
2018
NCT03787927
First Marketed Drug
2016
allogeneic hematopoietic stem cells (Hemacord)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Bloodworks | Bloodworks Northwest

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Blood Platelet Disorders (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 4